Latest Content

Generative AI has made pharma teams faster, but real value depends on redesigning commercialization workflows, especially as agentic AI raises the governance stakes.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.

Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.

ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.

Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.

Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.

Jon Hamrick, partner at Curatio Advisors, discusses how product attributes, company size and stakeholder alignment shape pharma commercialization strategy.

The rule targets PBMs, but rebate, price protection and formulary deals they strike with drugmakers will be disclosed to plan fiduciaries and open to audit.

DOL's final rule requires PBMs to disclose rebates and formulary incentives to large self-insured plans for plan years beginning on or after July 1, 2027.

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.